Article

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Neurology (Impact Factor: 8.3). 11/2006; 67(8):1411-20. DOI: 10.1212/01.wnl.0000240225.04000.1a
Source: PubMed

ABSTRACT Serotonin (5-HT) and norepinephrine (NE) are involved in pain modulation via descending inhibitory pathways in the brain and spinal cord.
To assess the efficacy of duloxetine, a dual reuptake inhibitor of 5-HT and NE, on the reduction of pain severity, as well as secondary outcome measures in patients with diabetic peripheral neuropathic pain (DPNP).
In this double-blind study, patients with DPNP and without comorbid depression were randomly assigned to treatment with duloxetine 60 mg once daily (QD), duloxetine 60 mg twice daily (BID), or placebo for 12 weeks. The primary outcome measure was the weekly mean score of 24-hour average pain severity on the 11-point Likert scale. Secondary measures and health outcome measures were also assessed.
Duloxetine 60 mg QD and 60 mg BID demonstrated improvement in the management of DPNP and showed rapid onset of action, with separation from placebo beginning at week 1 on the 24-hour average pain severity score. For all secondary measures for pain (except allodynia), mean changes showed an advantage of duloxetine over placebo, with no significant difference between 60 mg QD and 60 mg BID. Clinical Global Impression of Severity and Patient's Global Impression of Improvement evaluation demonstrated greater improvement on duloxetine- vs placebo-treated patients. Duloxetine showed no notable interference on diabetic controls, and both doses were safely administered.
This study confirms previous findings that duloxetine at 60 mg QD and 60 mg BID is effective and safe in the management of diabetic peripheral neuropathic pain.

1 Bookmark
 · 
183 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pain represents an immense clinical problem. With tens of millions of people in the United States alone suffering from the burden of debilitating chronic pain, there is a moral obligation to reduce this burden by improving the understanding of pain and treatment mechanisms, developing new therapies, optimizing and testing existing therapies, and improving access to evidence-based pain care. Here, we present a goal-oriented research agenda describing the American Pain Society's vision for the pain research aimed at tackling the most pressing issues in the field.
    Journal of Pain 10/2014; · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of Review: Diabetic Neuropathies are a heterogeneous by their symptoms, pattern of neurologic involvement, course, risk covariates, pathologic alterations, and underlying mechanisms that result into mono- and polyneuropathies, plexopathies and radiculopathies. It also ranges from subclinical functional impairment of cardiovascular reflexes and sudomotor functions to severe cardiovascular, gastrointestinal, or genitourinary dysfunction. Orthostatic hypotension, Resting tachycardia, and Heart Rate unresponsiveness to respiration are the hallmarks of Diabetic Autonomic Neuropathy. Diabetic Peripheral Neuropathy greatly affects all areas of a patient’s life, including mood, sleep, self-worth, independence, ability to work, and interpersonal relationships. This review provides an overview of definition, etiopathogenesis, clinical assessment, diagnosis and management of the patients with Diabetic Neuropathies. Summary and Results: Good clinical history and complete physical examination are the basis of assessment followed by therapeutic and laboratory studies. Strict glycemic control along with early detection and control of hyperlipidemia and hypertension, daily aspirin, smoking cessation and alcohol consumption in moderation may help to prevent, delay, or slow the progression of Diabetic Neuropathy. The main classes of agents used to treat Diabetic Peripheral Neuropathic pain include Tricyclic antidepressants, Anticonvulsants, Serotonin-Norepinephrine Reuptake Inhibitors, Opiates and Opiate-like substances, and topical medications. However, only two medications are approved specifically for the treatment of Diabetic Peripheral Neuropathic pain: Pregabalin and Duloxetine. Management must be individualized for each patient based on efficacy, side effects profiles and drug accessibility including cost. Keywords: Diabetic neuropathy; duloxetine; glycemic control; management; pregabalin.
    Annual Review and Research in Biology. 08/2013; 3(4):994-1012.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify distinct groups of patients with fibromyalgia (FM) with respect to multiple outcome measures. Data from 631 duloxetine-treated women in 4 randomized, placebo-controlled trials were included in a cluster analysis based on outcomes after up to 12 weeks of treatment. Corresponding classification rules were constructed using a classification tree method. Probabilities for transitioning from baseline to Week 12 category were estimated for placebo and duloxetine patients (Ntotal = 1188) using logistic regression. Five clusters were identified, from "worst" (high pain levels and severe mental/physical impairment) to "best" (low pain levels and nearly normal mental/physical function). For patients with moderate overall severity, mental and physical symptoms were less correlated, resulting in 2 distinct clusters based on these 2 symptom domains. Three key variables with threshold values were identified for classification of patients: Brief Pain Inventory (BPI) pain interference overall scores of <3.29 and <7.14, respectively, a Fibromyalgia Impact Questionnaire (FIQ) interference with work score of <2, and an FIQ depression score of >=5. Patient characteristics and frequencies per baseline category were similar between treatments; >80% of patients were in the 3 worst categories. Duloxetine patients were significantly more likely to improve after 12 weeks than placebo patients. A sustained effect was seen with continued duloxetine treatment. FM patients are heterogeneous and can be classified into distinct subgroups by simple descriptive rules derived from only 3 variables, which may guide individual patient management. Duloxetine showed higher improvement rates than placebo and had a sustained effect beyond 12 weeks.
    BMC Musculoskeletal Disorders 12/2014; 15(1):450. · 1.90 Impact Factor

Full-text (2 Sources)

Download
437 Downloads
Available from
May 23, 2014